Growth Equity Opportunities 18 VGE, LLC 13D and 13G filings for X4 Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-10-29 6:04 pm Purchase | 2025-10-27 | 13D | X4 Pharmaceuticals, Inc. XFOR | Growth Equity Opportunities 18 VGE, LLC | 5,057,610 6.200% | 2,813,952 (+125.42%) | Filing |
| 2025-08-15 4:54 pm Purchase | 2025-08-13 | 13D | X4 Pharmaceuticals, Inc. XFOR | Growth Equity Opportunities 18 VGE, LLC | 2,243,658 9.990% | 2,243,658 (New Position) | Filing |